Concepedia

Paul Mehan

PM

Statistics

Publications

10

Citations

687

H-Index

10

Active since

2009

Affiliations

Washington University in St. Louis(Current)

University of California, Irvine

Baptist Hospital

Missouri Baptist University

Mayo Clinic Hospital

Paul Mehan is an author at Washington University in St. Louis specializing in oncology, medicine, and cancer pharmacology.

Publications per year

2009–2024

10

Publications

10

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313

Ramesh K. Ramanathan, Shannon McDonough, Philip A. Philip et al. · Journal of Clinical Oncology · 2019 · 323 citations · Full text

Medicine, Oncology, Pharmacology +15

Primary plasma cell leukemia

Giridharan Ramsingh, Paul Mehan, Jingqin Luo et al. · Cancer · 2009 · 90 citations

Medicine, Hematology, Oncology +14

Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)

Michael J. Morris, Glenn Heller, David W. Hillman et al. · Journal of Clinical Oncology · 2023 · 52 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Cisplatin versus Cetuximab Given Concurrently with Definitive Radiation Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Jessica Ley, Paul Mehan, Tanya M. Wildes et al. · Oncology · 2013 · 46 citations · Full text

Medicine, Oncology, Radiation Oncology +12

Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).

Michael J. Morris, Glenn Heller, Alan H. Bryce et al. · Journal of Clinical Oncology · 2019 · 45 citations

Medicine, Endocrinology, Pharmacology +17

1–5 of 10